Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| REGENXBIO Inc.RGNX · Entity 2211 | Director | May 29, 2026 | June 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
REGENXBIO Inc.
Report date May 29, 2026 · Filed June 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 495,925 |
Reported balance
After 2026-05-29 transaction · row 1
1 source rowRow 1 · 2026-05-29 · Grant · Acquired 9,807 · Balance 495,925 F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer. |
| Stock Options (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.01 · Expires 2036-05-29 | Direct | 46,600 |
Reported balance
After 2026-05-29 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-29 · Grant · Acquired 46,600 · Balance 46,600 F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 100% of the shares subject to this RSU will vest on May 29, 2027 subject to the continuous service of the recipient to the Issuer.
F2: The option will vest May 29, 2027 subject to the continuous service of the optionee to the Issuer.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| December 10, 2020 Filed Dec 14, 2020 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 4,500 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-20-007249 · primarydocument.xml · derivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,170 Underlying: Common Stock · 4,500 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,500 | $40.00 | $180,000.00 |
DisclosureSEC source: 0001562180-20-007249 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| December 10, 2020 Filed Dec 14, 2020 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 4,500 | $0.85 | $3,825.00 |
DisclosureSEC source: 0001562180-20-007249 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 245,500 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| January 02, 2020 Filed Jan 6, 2020 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 270,000 | $0.00 Strike: $38.99 | $0.00 |
DisclosureSEC source: 0001562180-20-000214 · primarydocument.xml · derivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270,000 Underlying: Common Stock · 270,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 2, 2021 while the optionee provides continuous service to the Issuer. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 5,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-004927 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,670 Underlying: Common Stock · 5,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 7,773 | $39.91 | $310,220.43 |
DisclosureSEC source: 0001562180-19-004927 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 241,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $39.43 to $40.27. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,227 | $39.19 | $87,276.13 |
DisclosureSEC source: 0001562180-19-004927 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,773 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $38.43 to $39.41. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| September 19, 2019 Filed Sep 23, 2019 20:12 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 5,000 | $0.85 | $4,250.00 |
DisclosureSEC source: 0001562180-19-004927 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 251,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-004433 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 376 | $37.92 | $14,257.92 |
DisclosureSEC source: 0001562180-19-004433 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $37.90 to $37.99. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 14,624 | $37.54 | $548,984.96 |
DisclosureSEC source: 0001562180-19-004433 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,376 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $36.90 to $37.89. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| August 19, 2019 Filed Aug 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-004433 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-004035 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,300 | $49.97 | $114,931.00 |
DisclosureSEC source: 0001562180-19-004035 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.85 to $50.08. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 12,700 | $49.40 | $627,380.00 |
DisclosureSEC source: 0001562180-19-004035 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 248,300 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.85 to $49.83. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| July 19, 2019 Filed Jul 23, 2019 20:33 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-004035 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-003604 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,120 | $53.25 | $219,390.00 |
DisclosureSEC source: 0001562180-19-003604 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $52.77 to $53.65. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,880 | $52.27 | $568,697.60 |
DisclosureSEC source: 0001562180-19-003604 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,120 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $51.77 to $52.76. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| June 19, 2019 Filed Jun 21, 2019 20:11 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-003604 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-003056 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 300 | $43.99 | $13,197.00 |
DisclosureSEC source: 0001562180-19-003056 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 10,559 | $43.32 | $457,415.88 |
DisclosureSEC source: 0001562180-19-003056 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,300 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $42.92 to $43.85. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,141 | $42.08 | $174,253.28 |
DisclosureSEC source: 0001562180-19-003056 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 256,859 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $41.92 to $42.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 20, 2019 Filed May 22, 2019 20:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-003056 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · derivative · entry 7 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 144,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F6 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 100 | $53.05 | $5,305.00 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 6 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,300 | $52.33 | $68,029.00 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,100 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F5 · price: This transaction was executed in multiple trades at prices ranging from $51.84 to $52.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,270 | $51.07 | $166,998.90 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 247,400 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $50.81 to $51.66. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 6,929 | $50.31 | $348,597.99 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 250,670 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $49.81 to $50.80. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,401 | $49.29 | $167,635.29 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,599 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $48.81 to $49.79. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| April 22, 2019 Filed Apr 24, 2019 20:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-002331 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-002005 · primarydocument.xml · derivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 159,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 9,130 | $58.74 | $536,296.20 |
DisclosureSEC source: 0001562180-19-002005 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $58.51 to $59.26. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 5,870 | $58.21 | $341,692.70 |
DisclosureSEC source: 0001562180-19-002005 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,130 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $57.51 to $58.50. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| March 19, 2019 Filed Mar 21, 2019 20:17 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-002005 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 8,066 | $47.84 | $385,877.44 |
DisclosureSEC source: 0001562180-19-001047 · primarydocument.xml · nonDerivative · entry 4 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.57 to $48.15. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,522 | $47.30 | $166,590.60 |
DisclosureSEC source: 0001562180-19-001047 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 254,066 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.56 to $47.54. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 15, 2019 Filed Feb 19, 2019 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,412 | $45.96 | $156,815.52 |
DisclosureSEC source: 0001562180-19-001047 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 257,588 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.48 to $46.44. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-001047 · primarydocument.xml · derivative · entry 5 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,670 Underlying: Common Stock · 15,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| February 14, 2019 Filed Feb 19, 2019 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 15,000 | $0.85 | $12,750.00 |
DisclosureSEC source: 0001562180-19-001047 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 261,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionEmployee Stock Option (Right to Buy) · Derivative | 45,000 | $0.00 Strike: $0.85 | $0.00 |
DisclosureSEC source: 0001562180-19-000759 · primarydocument.xml · derivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,670 Underlying: Common Stock · 45,000 shares Expires 2024-09-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: The previously granted option, representing a right to purchase a total of 708,200 shares, became exercisable as follows: 474,490 of the shares subject to the option are initial shares ("Initial Shares") and 233,710 of the shares subject to the option are contingent shares ("Contingent Shares"). 120,394 of the Initial Shares vested on September 17, 2014, 88,524 of the Initial Shares vested on September 17, 2015 and an additional 7,377 of the Initial Shares vested upon each month of continuous service to the Company thereafter. 25% of the Contingent Shares were deemed vested as of September 17, 2014 on January 13, 2015 due to a subsequent event. The remainder of the Contingent Shares vested over four years of service following September 17, 2014, with 25% of the remaining 75% of Contingent Shares having vested on September 17, 2015 and the remaining Contingent Shares having vested in 36 equal monthly installments thereafter. Read SEC document |
| February 01, 2019 Filed Feb 5, 2019 21:21 UTC | REGENXBIO Inc. RGNX · Entity 2211 | Exercise / conversionCommon Stock | 45,000 | $0.85 | $38,250.00 |
DisclosureSEC source: 0001562180-19-000759 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 246,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 3,140 | $44.40 | $139,416.00 |
DisclosureSEC source: 0001562180-19-000337 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 201,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $44.13 to $44.62. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 15, 2019 Filed Jan 17, 2019 21:18 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 11,860 | $43.70 | $518,282.00 |
DisclosureSEC source: 0001562180-19-000337 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 204,140 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $43.13 to $44.12. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| January 03, 2019 Filed Jan 7, 2019 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | GrantStock Option (Right to Buy) · Derivative | 190,000 | $0.00 Strike: $40.82 | $0.00 |
DisclosureSEC source: 0001562180-19-000218 · primarydocument.xml · derivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,000 Underlying: Common Stock · 190,000 shares Expires 2029-01-03 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 36 months following January 3, 2020 while the optionee provides continuous service to the Issuer. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 4,408 | $47.74 | $210,437.92 |
DisclosureSEC source: 0001562180-18-005050 · primarydocument.xml · nonDerivative · entry 3 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 216,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F4 · price: This transaction was executed in multiple trades at prices ranging from $47.44 to $48.125. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 2,988 | $46.81 | $139,868.28 |
DisclosureSEC source: 0001562180-18-005050 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 220,408 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $46.44 to $47.435. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 17, 2018 Filed Dec 19, 2018 21:20 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 7,604 | $46.11 | $350,620.44 |
DisclosureSEC source: 0001562180-18-005050 · primarydocument.xml · nonDerivative · entry 1 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 223,396 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F2 · price: This transaction was executed in multiple trades at prices ranging from $45.43 to $46.40. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:19 UTC | REGENXBIO Inc. RGNX · Entity 2211 | SaleCommon Stock | 1,300 | $61.33 | $79,729.00 |
DisclosureSEC source: 0001562180-18-004849 · primarydocument.xml · nonDerivative · entry 2 Mills Kenneth T. · CIK 0001652824 · Director · President and CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 231,000 F1 · kind: This transaction was effected pursuant to a Rule 10b5-1 trading plan. F3 · price: This transaction was executed in multiple trades at prices ranging from $61.10 to $61.82. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.